Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Exact Sciences Corporation    EXAS

EXACT SCIENCES CORPORATION

(EXAS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

EXACT SCIENCES CORP : Other Events (form 8-K)

11/27/2020 | 03:40pm EST
Item 8.01 Other Events.



On November 27, 2020, Exact Sciences Corporation (the "Company") reported that Kevin Conroy, Chairman and Chief Executive Officer has entered into a pre-arranged, written stock trading plan (the "Plan") that is intended to satisfy the requirements of Rule 10b5-1(c) under the Securities Exchange Act of 1934.

Commencing in August 2021, on a date that is expected to be after the date the Company releases earnings for the second quarter of 2021, Mr. Conroy intends to periodically sell under the Plan shares in amounts that, over any twelve (12) month period, are not more than ten percent (10%) of his current aggregate vested and unvested equity interest in the Company. Sales under the Plan would be in addition to sales that Mr. Conroy makes under an existing "sell-to-cover" written stock trading plan that results in the sale of a portion of the shares resulting from vesting restricted stock unit awards to cover a portion of the taxes due upon such vesting. Mr. Conroy has informed the Company that he will use the proceeds from sales under the Plan (1) to pay the applicable exercise price and a portion of the taxes due upon the sale of shares, the exercise of options, and the vesting of restricted stock units and (2) for financial planning purposes.

Transactions under the Plan will be disclosed publicly through Form 144 and Form 4 filings with the Securities and Exchange Commission, as required by law.

On November 27, 2019, the Company disclosed on a Current Report on Form 8-K that Mr. Conroy entered into a separate pre-arranged, written stock trading plan (the "2019 Plan"). It is anticipated that any sales under the 2019 Plan shall have concluded prior to August 2021.

It is possible that other executive officers and directors of the Company may enter into similar stock trading plans in the future. Except as may be required by law, the Company does not undertake to report on stock trading plans by other Company officers or directors, nor report modifications, terminations or other activities under Mr. Conroy's Plan or the plan of any other individual.

                                       2

© Edgar Online, source Glimpses

All news about EXACT SCIENCES CORPORATION
01/21EXACT SCIENCES : SVB Leerink Adjusts Exact Sciences' Price Target to $170 From $..
MT
01/15EXACT SCIENCES CORP : Change in Directors or Principal Officers (form 8-K)
AQ
01/13EXACT SCIENCES : Licenses Targeted Digital Sequencing Method in Cancer Screening
MT
01/12EXACT SCIENCES : Oppenheimer Adjusts Price Target for Exact Sciences to $161 Fro..
MT
01/11INSIDER TRENDS : 90-Day Insider Buying Trend Reduced with Sale of Guidewire Soft..
MT
01/11SECTOR UPDATE : Narrow Rise for Most Health Care Stocks
MT
01/11EXACT SCIENCES : Projects Q4 Revenue Above Street Forecasts
MT
01/08EXACT SCIENCES : EXAS) Insider Makes Significant Share Sale
MT
01/07INSIDER TRENDS : Exact Sciences Insider Extends 90-Day Selling Trend
MT
01/05Jefferies, Exxon rise; Exact Sciences, WW International fall
AQ
More news
Financials (USD)
Sales 2020 1 469 M - -
Net income 2020 -396 M - -
Net cash 2020 182 M - -
P/E ratio 2020 -49,8x
Yield 2020 -
Capitalization 21 763 M 21 763 M -
EV / Sales 2020 14,7x
EV / Sales 2021 11,9x
Nbr of Employees 4 110
Free-Float 99,1%
Chart EXACT SCIENCES CORPORATION
Duration : Period :
Exact Sciences Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EXACT SCIENCES CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Average target price 150,00 $
Last Close Price 136,85 $
Spread / Highest target 24,2%
Spread / Average Target 9,61%
Spread / Lowest Target -44,5%
EPS Revisions
Managers and Directors
NameTitle
Kevin T. Conroy Chairman, President & Chief Executive Officer
Ana Hooker Senior Vice President-Operations
Jeffrey Thomas Elliott Chief Financial Officer
Graham Peter Lidgard Chief Science Officer, SVP-Research & Development
Sandra Statz SVP-Clinical & Regulatory Affairs
Sector and Competitors
1st jan.Capitalization (M$)
EXACT SCIENCES CORPORATION3.29%21 763
GUARDANT HEALTH, INC.14.36%14 987
BGI GENOMICS CO., LTD.31.71%9 670
INVITAE CORPORATION14.06%9 123
ADAPTIVE BIOTECHNOLOGIES CORPORATION-7.59%8 499
IOVANCE BIOTHERAPEUTICS, INC.-3.86%6 544